Prevalence of Metabolic Syndrome in Baluch Women in Chabahar

Prevalence of overweight and obesity among Iranian population: a systematic review and meta-analysis

BACKGROUND

Obesity is a major risk factor for chronic diseases. Politicians and practitioners should be aware of the dramatic increase in obesity and its subsequent complications to prevent associated health risks. This systematic review aimed to provide better insight into the prevalence of overweight and obesity in the Iranian population.

METHOD

An evaluation was conducted on all published observational studies from both national (SID, Irandoc, Iranmedex) and international (Web of Knowledge, PubMed, Scopus) sources, which reported the prevalence of overweight/obesity among normal population samples, between January 2012 and December 2021.

RESULT

A total of 152 eligible studies were included in this meta-analysis. Of the 152 selected studies, 74 reported the prevalence of overweight/obesity in patients aged ≤ 18 years, and 61 studies in adults. In the rest of the articles (17 studies), the results were reported for a combination of these age groups. The prevalence of overweight and obesity in Iran was estimated at 20.1 (95% CI 17.92-22.30) and 13.44 (95% CI 11.76-15.22), respectively. This percentage (95% CI) was 11.71 (10.98-12.46) for overweight and 8.08 (7.02-9.22) for obesity in those aged ≤ 18 years, and 35.26 (32.61-37.99) for overweight and 21.38 (19.61-23.20) for obesity in those aged > 18 years. The overall prevalence of overweight and obesity in the entire population was 35.09% (95% CI 31.31-38.98).

CONCLUSION

As obesity is on the rise in Iran, we should seek both weight loss strategies and ways to control comorbidities associated with high BMI.

Prevalence and Incidence of Metabolic Syndrome in Iran: A Systematic Review and Meta-Analysis

Metabolic syndrome (MetS) is a predictor of several diseases such as cardiovascular diseases, diabetes, dyslipidemia, stroke, osteoarthritis, certain cancers, and death leading to public health concern in most societies. We aimed to estimate the pooled prevalence and incidence of MetS in Iranian population through a meta-analysis study. We included cross-sectional and cohort studies to estimate the overall prevalence and incidence rates of MetS in Iran National databases including MagIran, Science Information Database, IranMedex, and international databases including Medline, Web of Sciences, and Scopus were searched up to October 2017. Finally, 125 studies were included. The total sample size was 472,401 with a mean age of 38 ± 7.8 years. The overall pooled prevalence and incidence rate among the general population of Iran was 0.26 (95% CI: 0.26, 0.29) and 97.96 (95% CI: 75.98, 131.48), respectively. The pooled prevalence of MetS was higher in females and in urban areas. The highest and lowest prevalence of MetS was obtained by the Iranian definition criteria (0.43) and the NHANES III (0.12). The highest and lowest incidence rates of MetS were obtained by IDF (144.07 per 1000) and the JIS (89.73 per 1000). The prevalence of MetS was higher in women and those living in urban areas. Furthermore, the prevalence of MetS increased with increasing age in both genders.

Prevalence of metabolic syndrome in Iran: A meta-analysis of 69 studies

AIMS

Metabolic syndrome increases the risk of chronic diseases including cardiovascular diseases and diabetes. The present study investigated the prevalence of metabolic syndrome in Iran.

MATERIALS AND METHODS

Published articles in English and Persian during 2000-2016 identified using keywords of prevalence, metabolic syndrome, and Iran in the following databases: Web of Science, PubMed, Scopus, Google scholar, SID and Magiran. Random effect model used to calculate the pooled estimates. Heterogeneity of studies assessed using Q statistic, and geographical distribution of metabolic syndrome demonstrated via GIS map. Data were analyzed by STATA-11.

RESULTS

The overall prevalence of metabolic syndrome was 30.4% (95%CI: 28.3-32.6) with no significant heterogeneity by diagnostic criteria. The lowest frequency was reported in Sistan and Baluchestan Province [18.3% (95% CI: 12.9-25.8)] compared to the highest in Bushehr [57.8% (95% CI: 41.8-80.0)]. It was significantly more prevalent in women [(34.8% (95%CI: 31.2-38.8)] compared to men [25.7% (95%CI: 23.4-28.3)] (P = 0.001)]. A significant increasing trend (P = 0.001) was observed in different age groups, as metabolic syndrome increased from 12.1% (95% CI: 9.37-15.6) in 20-29 years-old age group to 51.7% (95%CI: 47.4-56.4) in the over 60 years-old age group.

CONCLUSIONS

Approximately one-third of Iranian adults have metabolic syndrome which varied by regions, age and gender. Then, appropriate intervention based on behavioral patterns of inhabitants and local conditions may help to reduce the burden of disease.

Serum Progranulin Levels in Type 2 Diabetic Patients with Metabolic Syndrome

Introduction. The role of progranulin in individuals with metabolic syndrome is not exactly clear.We aimed to assess the serum level of progranulin in type 2 diabetic patients with and without metabolic syndrome and compare them with healthy controls.

Methods. The study included 60 patients with type 2 diabetes and 30 healthy individuals as control groups. Biochemical parameters and progranulin levels were determined.

Results. Subjects with metabolic syndrome showed significantly higher levels of triglyceride, waist circumference, BMI, systolic and diastolic blood pressure than subjects without metabolic syndrome and the control groups, while HDL-cholesterol level was significantly lower in subjects with metabolic syndrome. Fasting blood sugar was significantly higher in type 2 diabetic patients than in the control groups. Serum level of progranulin was slightly increased in subjects with metabolic syndrome. Serum progranulin level had no significant relationship with metabolic syndrome components.

Conclusions. Serum progranulin was also not dependent on cardiometabolic risk factors for subjects with metabolic syndrome, but it could be considered for the management of type 2 diabetes mellitus. Further studies are recommended to explain the effect of progranulin on the pathogenesis of metabolic risk factors.